Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study
| Autor: | Alexander R. Rosenkranz, Josef Kovarik, Emanuel Zitt, Frank Pétavy, Katharina Kodras, Bruno Watschinger, Christine Jäger, Helmut Graf, Sabine Horn, Manfred Eigner |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Cinacalcet medicine.drug_class Calcimimetic medicine.medical_treatment Urology Naphthalenes Sevelamer Risk Assessment Cohort Studies Risk Factors medicine Prevalence Humans Dialysis Hyperparathyroidism business.industry General Medicine Middle Aged medicine.disease Phosphate binder Surgery Treatment Outcome Austria Secondary hyperparathyroidism Female Hyperparathyroidism Secondary business Cohort study medicine.drug |
| Zdroj: | Wiener klinische Wochenschrift. 123(1-2) |
| ISSN: | 1613-7671 |
| Popis: | BACKGROUND: Despite extensive use of standard therapy for secondary hyperparathyroidism (sHPT) in dialysis patients, still most patients do not achieve the recommended treatment targets. In a pan-European observational study (ECHO), the effectiveness of the calcimimetic cinacalcet for the treatment of sHPT was evaluated in real-world clinical practice. A sub-analysis of the entire Austrian study cohort is presented. METHODS: Adult dialysis patients who had initiated cinacalcet therapy were included. Data on biochemical parameters of bone and mineral metabolism (intact parathyroid hormone [iPTH], calcium [Ca] and phosphorus [P]) and concurrent medication were collected 6 months prior to the initiation of cinacalcet, at initiation (baseline) and after up to 12 months of active treatment. RESULTS: A total of 320 patients (mean age (±SD): 56 (±14) years) from 34 Austrian dialysis centres were enrolled. At baseline, patients presented with elevated serum iPTH (median 605 pg/ml) and hyperphosphataemia (median 2.1 mmol/l). After 12 months of cinacalcet treatment, serum iPTH (median percentage change –48%), calcium (–2%) and phosphorus (–6%) decreased. The greatest iPTH reduction (–66%) was found in patients with most severe sHPT (>800 pg/ml at baseline). The proportion of patients achieving the recommended NKF/K-DOQI™ treatment targets increased from baseline to month 12 for iPTH (3–36%) and phosphorus (24 to 39%) and remained stable for calcium (51 to 50%), respectively. No patient had all 3 parameters simultaneously within NKF/K-DOQI™ treatment targets at baseline, while 7% of patients achieved this treatment goal after 12 months. During the study the use of the phosphate binder sevelamer remained fairly stable, while the relative percentage use of calcium-based phosphate binders increased and the usage of aluminium-containing binders decreased; vitamin D analogue use remained stable. CONCLUSION: Additional use of cinacalcet improved biochemical parameters of bone and mineral metabolism and enabled more patients to achieve and maintain the KDOQI™ treatment targets for serum iPTH, calcium and phosphorus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink